特発性頭蓋内圧亢進症治療の世界市場レポート 2025年

特発性頭蓋内圧亢進症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で19億1,000万米ドルに成長します。予測期間中の成長は、デジタルヘルスソリューションの採用拡大、生活習慣関連疾患の増加、遠隔医療の利用拡大、高度な診断ツールの利用可能性の拡大、個別化医療に対する需要の高まりに起因すると考えられます。予測期間における主な動向には、AI駆動型診断ツールの使用、標的治療の開発、非侵襲的画像技術の進歩、新しい体重管理薬の導入、カスタマイズ可能なシャントデバイスの作成などがあります。

肥満の有病率の増加は、今後数年間における特発性頭蓋内圧亢進症（IIH）治療市場の拡大を促進すると予想されます。肥満は体脂肪過多を特徴とする病状であり、健康全般に害を及ぼす可能性があります。肥満の増加は、座りがちなライフスタイルの増加やカロリーの高い加工食品の摂取が主な原因となっています。肥満は、特発性頭蓋内圧亢進症の発症に重要な役割を果たす脳脊髄液の過剰産生とその吸収を阻害することにより、頭蓋内圧亢進の一因となります。例えば、英国政府部門である健康改善・格差対策室の2024年の報告書によると、2022年から2023年の間に、イングランドの18歳以上の成人の64.0％が過体重または肥満に分類されました。この数字は、2021年から2022年にかけて報告された63.8％とほぼ同じです。したがって、肥満率の上昇が特発性頭蓋内圧亢進症治療市場の成長を大きく促進しています。

特発性頭蓋内圧亢進症治療市場の主要企業は、頭蓋内圧の管理と関連症状の緩和を目的とした革新的な治療法の開発に注力しています。これらの治療法は、先進的なドラッグデリバリーシステムと標的治療アプローチによって患者の予後を改善し、全体的なケアと生活の質を高めることを目指しています。例えば、2022年11月、オーストラリアを拠点とするバイオ医薬品会社インベックス・セラピューティクスは、特発性頭蓋内圧亢進症（IIH）治療薬プレセンディン（徐放性エキセナチド）の第III相IIH EVOLVE臨床試験を開始するための承認をニュージーランド医薬品医療機器安全庁（MEDSAFE）から取得しました。この承認は、ニュージーランドの医療・障害倫理委員会（New Zealand Health and Disability Ethics Committee）からの承認とともに、インベックス社がこの神経疾患の治療成績を改善することを目的として、新たにIIHと診断された患者240人を対象に、最大40の世界の臨床施設で試験を実施することを可能にするものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界特発性頭蓋内圧亢進症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の特発性頭蓋内圧亢進症治療市場：成長率分析
• 世界の特発性頭蓋内圧亢進症治療市場の実績：規模と成長, 2019-2024
• 世界の特発性頭蓋内圧亢進症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界特発性頭蓋内圧亢進症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の特発性頭蓋内圧亢進症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 手術
• 治療法
• 世界の特発性頭蓋内圧亢進症治療市場治療投与による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口投与
• 脊髄内投与
• 世界の特発性頭蓋内圧亢進症治療市場診断タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経画像検査
• 腰椎穿刺
• 視野検査
• 世界の特発性頭蓋内圧亢進症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• 世界の特発性頭蓋内圧亢進症治療市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 利尿剤
• コルチコステロイド
• アセタゾラミド
• 世界の特発性頭蓋内圧亢進症治療市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• シャント手術
• 視神経鞘窓術
• ステント留置術
• 世界の特発性頭蓋内圧亢進症治療市場、治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 体重管理プログラム
• ライフスタイルの変更
• 理学療法

第7章 地域別・国別分析

• 世界の特発性頭蓋内圧亢進症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の特発性頭蓋内圧亢進症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 特発性頭蓋内圧亢進症治療市場：競合情勢
• 特発性頭蓋内圧亢進症治療市場：企業プロファイル
  • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
  • Philips Healthcare Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GE HealthCare Technologies Inc.
• Teva Pharmaceuticals
• Boston Scientific Corporation
• Henry schein
• Sun Pharmaceutical Industries
• Zydus LifeSciences
• Topcon Corporation
• Natus Medical Incorporated
• Canon Medical Systems Corporation
• Carl Zeiss Meditec AG
• Optopol Technology
• Strides Pharma
• NIDEK Co.
• Haag-Streit AG
• Invex Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 特発性頭蓋内圧亢進症治療市場2029：新たな機会を提供する国
• 特発性頭蓋内圧亢進症治療市場2029：新たな機会を提供するセグメント
• 特発性頭蓋内圧亢進症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Idiopathic intracranial hypertension (IIH) treatment involves medical and surgical approaches aimed at lowering intracranial pressure and preventing complications such as vision loss. These treatments may include lifestyle modifications, such as weight loss, medications such as acetazolamide to reduce fluid buildup, and surgical interventions, including shunt placement or optic nerve sheath fenestration in more severe cases.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main treatment types for idiopathic intracranial hypertension include medications, surgeries, and therapies. Medications are used to reduce cerebrospinal fluid production, relieve symptoms such as headaches and visual disturbances, and manage underlying conditions. These medications are typically administered orally or intrathecally. Diagnostic methods for IIH include neuroimaging, lumbar puncture, and visual field tests, and treatments are generally provided in hospitals, specialized clinics, or ambulatory surgical centers.

The idiopathic intracranial hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides idiopathic intracranial hypertension treatment market statistics, including the idiopathic intracranial hypertension treatment industry's global market size, regional shares, competitors with a idiopathic intracranial hypertension treatment market share, detailed idiopathic intracranial hypertension treatment market segments, market trends and opportunities, and any further data you may need to thrive in the idiopathic intracranial hypertension treatment industry. This idiopathic intracranial hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The idiopathic intracranial hypertension treatment market size has grown strongly in recent years. It will grow from$1.38 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to several factors, including the rising prevalence of obesity, increased healthcare spending, a growing emphasis on minimally invasive surgical techniques, the increasing prevalence of comorbid conditions, and a higher demand for advanced ophthalmologic diagnostic tools.

The idiopathic intracranial hypertension treatment market size is expected to see strong growth in the next few years. It will grow to$1.91 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the growing adoption of digital health solutions, the rise in lifestyle-related disorders, increased use of telemedicine, greater availability of advanced diagnostic tools, and a growing demand for personalized medicine. Key trends in the forecast period include the use of AI-driven diagnostic tools, the development of targeted therapies, advancements in non-invasive imaging techniques, the introduction of new weight management medications, and the creation of customizable shunt devices.

The growing prevalence of obesity is expected to drive the expansion of the idiopathic intracranial hypertension (IIH) treatment market in the coming years. Obesity is a medical condition characterized by excessive body fat, which can harm overall health. The rise in obesity is largely attributed to increasingly sedentary lifestyles and the consumption of calorie-dense processed foods. Obesity contributes to increased intracranial pressure by promoting the overproduction of cerebrospinal fluid and impairing its absorption, which plays a key role in the development of idiopathic intracranial hypertension. For instance, according to a 2024 report from the Office for Health Improvement and Disparities, a UK government department, 64.0% of adults aged 18 and older in England were classified as overweight or obese between 2022 and 2023. This figure is nearly the same as the 63.8% reported for the 2021 to 2022 period. Therefore, the rising obesity rates are significantly driving the growth of the idiopathic intracranial hypertension treatment market.

Leading companies in the idiopathic intracranial hypertension treatment market are focusing on developing innovative therapies aimed at managing intracranial pressure and alleviating associated symptoms. These therapies aim to improve patient outcomes through advanced drug delivery systems and targeted treatment approaches, thereby enhancing overall care and quality of life. For example, in November 2022, Invex Therapeutics, an Australia-based biopharmaceutical company, received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to begin the Phase III IIH EVOLVE clinical trial for Presendin (sustained-release exenatide) in the treatment of idiopathic intracranial hypertension (IIH). This approval, along with clearance from the New Zealand Health and Disability Ethics Committee, allows Invex to conduct the trial with 240 newly diagnosed IIH patients at up to 40 global clinical sites, aiming to improve treatment outcomes for this neurological condition.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for $12 billion. This acquisition enhances Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a novel antipsychotic with a unique mechanism of action and a promising efficacy and safety profile. The acquisition aligns with Bristol Myers Squibb's long-term growth strategy and strengthens its ability to address unmet needs in neurodegenerative conditions. Karuna Therapeutics Inc. is a US-based biopharmaceutical company that focuses on developing therapies for neurological disorders.

Major players in the idiopathic intracranial hypertension treatment market are Siemens AG, Medtronic plc, Mayo Clinic, Becton Dickinson and Company, Philips Healthcare, GE HealthCare Technologies Inc., Teva Pharmaceuticals, Boston Scientific Corporation, Henry schein, Sun Pharmaceutical Industries, Zydus LifeSciences, Topcon Corporation, Natus Medical Incorporated, Canon Medical Systems Corporation, Carl Zeiss Meditec AG, Optopol Technology, Strides Pharma, NIDEK Co., Haag-Streit AG, Invex Therapeutics, and Metrovision.

North America was the largest region in the idiopathic intracranial hypertension treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in idiopathic intracranial hypertension treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the idiopathic intracranial hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The idiopathic intracranial hypertension treatment market consists of revenues earned by entities by providing services such as diagnostic imaging services, nutritional counseling, optic nerve sheath fenestration procedures, ophthalmologic evaluations, and visual field monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The idiopathic intracranial hypertension treatment market also includes sales of shunt systems, surgical instruments, intracranial pressure monitoring devices, and optical coherence tomography (OCT). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Idiopathic Intracranial Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on idiopathic intracranial hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for idiopathic intracranial hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic intracranial hypertension treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medications; Surgeries; Therapies
• 2) By Treatment Administration: Oral Administration; Intrathecal Administration
• 3) By Diagnostic Type: Neuroimaging; Lumbar Puncture; Visual Field Tests
• 4) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centres
• Subsegments:
• 1) By Medications: Diuretics; Corticosteroids; Acetazolamide
• 2) By Surgeries: Shunt Surgery; Optic Nerve Sheath Fenestration; Stenting
• 3) By Therapies: Weight Management Programs; Lifestyle Modifications; Physical Therapy
• Companies Mentioned: Siemens AG; Medtronic plc; Mayo Clinic; Becton Dickinson and Company; Philips Healthcare
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Idiopathic Intracranial Hypertension Treatment Market Characteristics

3. Idiopathic Intracranial Hypertension Treatment Market Trends And Strategies

4. Idiopathic Intracranial Hypertension Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Idiopathic Intracranial Hypertension Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Idiopathic Intracranial Hypertension Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Idiopathic Intracranial Hypertension Treatment Market Growth Rate Analysis
• 5.4. Global Idiopathic Intracranial Hypertension Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Idiopathic Intracranial Hypertension Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Idiopathic Intracranial Hypertension Treatment Total Addressable Market (TAM)

6. Idiopathic Intracranial Hypertension Treatment Market Segmentation

• 6.1. Global Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgeries
• Therapies
• 6.2. Global Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Administration
• Intrathecal Administration
• 6.3. Global Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neuroimaging
• Lumbar Puncture
• Visual Field Tests
• 6.4. Global Idiopathic Intracranial Hypertension Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• 6.5. Global Idiopathic Intracranial Hypertension Treatment Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diuretics
• Corticosteroids
• Acetazolamide
• 6.6. Global Idiopathic Intracranial Hypertension Treatment Market, Sub-Segmentation Of Surgeries, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Shunt Surgery
• Optic Nerve Sheath Fenestration
• Stenting
• 6.7. Global Idiopathic Intracranial Hypertension Treatment Market, Sub-Segmentation Of Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Weight Management Programs
• Lifestyle Modifications
• Physical Therapy

7. Idiopathic Intracranial Hypertension Treatment Market Regional And Country Analysis

• 7.1. Global Idiopathic Intracranial Hypertension Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Idiopathic Intracranial Hypertension Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market

• 8.1. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Idiopathic Intracranial Hypertension Treatment Market

• 9.1. China Idiopathic Intracranial Hypertension Treatment Market Overview
• 9.2. China Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Idiopathic Intracranial Hypertension Treatment Market

• 10.1. India Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Idiopathic Intracranial Hypertension Treatment Market

• 11.1. Japan Idiopathic Intracranial Hypertension Treatment Market Overview
• 11.2. Japan Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Idiopathic Intracranial Hypertension Treatment Market

• 12.1. Australia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Idiopathic Intracranial Hypertension Treatment Market

• 13.1. Indonesia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Idiopathic Intracranial Hypertension Treatment Market

• 14.1. South Korea Idiopathic Intracranial Hypertension Treatment Market Overview
• 14.2. South Korea Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Idiopathic Intracranial Hypertension Treatment Market

• 15.1. Western Europe Idiopathic Intracranial Hypertension Treatment Market Overview
• 15.2. Western Europe Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Idiopathic Intracranial Hypertension Treatment Market

• 16.1. UK Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Idiopathic Intracranial Hypertension Treatment Market

• 17.1. Germany Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Idiopathic Intracranial Hypertension Treatment Market

• 18.1. France Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Idiopathic Intracranial Hypertension Treatment Market

• 19.1. Italy Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Idiopathic Intracranial Hypertension Treatment Market

• 20.1. Spain Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Idiopathic Intracranial Hypertension Treatment Market

• 21.1. Eastern Europe Idiopathic Intracranial Hypertension Treatment Market Overview
• 21.2. Eastern Europe Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Idiopathic Intracranial Hypertension Treatment Market

• 22.1. Russia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Idiopathic Intracranial Hypertension Treatment Market

• 23.1. North America Idiopathic Intracranial Hypertension Treatment Market Overview
• 23.2. North America Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Idiopathic Intracranial Hypertension Treatment Market

• 24.1. USA Idiopathic Intracranial Hypertension Treatment Market Overview
• 24.2. USA Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Idiopathic Intracranial Hypertension Treatment Market

• 25.1. Canada Idiopathic Intracranial Hypertension Treatment Market Overview
• 25.2. Canada Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Idiopathic Intracranial Hypertension Treatment Market

• 26.1. South America Idiopathic Intracranial Hypertension Treatment Market Overview
• 26.2. South America Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Idiopathic Intracranial Hypertension Treatment Market

• 27.1. Brazil Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Idiopathic Intracranial Hypertension Treatment Market

• 28.1. Middle East Idiopathic Intracranial Hypertension Treatment Market Overview
• 28.2. Middle East Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Idiopathic Intracranial Hypertension Treatment Market

• 29.1. Africa Idiopathic Intracranial Hypertension Treatment Market Overview
• 29.2. Africa Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Treatment Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Idiopathic Intracranial Hypertension Treatment Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Idiopathic Intracranial Hypertension Treatment Market Competitive Landscape And Company Profiles

• 30.1. Idiopathic Intracranial Hypertension Treatment Market Competitive Landscape
• 30.2. Idiopathic Intracranial Hypertension Treatment Market Company Profiles
  • 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Philips Healthcare Overview, Products and Services, Strategy and Financial Analysis

31. Idiopathic Intracranial Hypertension Treatment Market Other Major And Innovative Companies

• 31.1. GE HealthCare Technologies Inc.
• 31.2. Teva Pharmaceuticals
• 31.3. Boston Scientific Corporation
• 31.4. Henry schein
• 31.5. Sun Pharmaceutical Industries
• 31.6. Zydus LifeSciences
• 31.7. Topcon Corporation
• 31.8. Natus Medical Incorporated
• 31.9. Canon Medical Systems Corporation
• 31.10. Carl Zeiss Meditec AG
• 31.11. Optopol Technology
• 31.12. Strides Pharma
• 31.13. NIDEK Co.
• 31.14. Haag-Streit AG
• 31.15. Invex Therapeutics

32. Global Idiopathic Intracranial Hypertension Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Idiopathic Intracranial Hypertension Treatment Market

34. Recent Developments In The Idiopathic Intracranial Hypertension Treatment Market

35. Idiopathic Intracranial Hypertension Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Idiopathic Intracranial Hypertension Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Idiopathic Intracranial Hypertension Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Idiopathic Intracranial Hypertension Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34877_Idiopathic_Intracranial_Hypertension_Treatment_GMR_2025